Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial-MedSci.cn

Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Qin, SK; Li, Q; Gu, SZ; Chen, XM; Lin, LZ; Wang, ZS; Xu, AB; Chen, X; Zhou, CC; Ren, ZG; Yang, L; Xu, L; Bai, YX; Chen, L; Li, J; Pan, HM; Cao, BW; Fang, WJ; Wu, W; Wang, G; Cheng, Y; Yu, Z; Zhu, X; Jiang, D; Lu, YY; Wang, HM; Xu, JM; Bai, L; Liu, YP; Lin, HL; Wu, CP; Zhang, Y; Yan, P; Jin, CL; Zou, JJ

Qin, SK (corresponding author), Nanjing Chinese Med Univ, Canc Ctr, Bayi Hosp, Nanjing 210002, Peoples R China.

Abstract

Background Inhibition of vascular endothelial growth factor receptor (VEGFR) has shown antitumour activity in advanced hepatocellular carcinoma, but f......

Full Text Link

Links

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

科室

工具

服务